Skip to Main Content

Paper Details

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.
Neuro Oncol
160
2022
MGMT promoter, NIVO, Patients, TMZ, glioblastoma, methylated, patients, temozolomide
Author NameAffiliation
Michael WellerUniversity Hospital and University of Zurich
Ahmed IdbaihSorbonne Universite, Institut du Cerveau-Paris Brain Institute-ICM, Inserm, CNRS, Hopital Universitaire La Pitie Salpetriere
Gaetano FinocchiaroNeurological Institute C. Besta
Gaetano FinocchiaroNeurological Institute C. Besta
Ashley L SumrallLevine Cancer Institute
Deepti M Warad
  • 1 - 6

Datasets

Release 1.2